Treatment with synthetic DMARDs | First TNF antagonist monotherapy | First TNF antagonist plus one csDMARD | First TNF antagonist plus two or more csDMARDs | Total | Pp* | ||||
---|---|---|---|---|---|---|---|---|---|
n, % | 234 | 21 | 766 | 67 | 136 | 12 | 1.136 | 100 | |
Baseline DAS28 score (mean ± SD) | 5.9 | 1.0 | 5.7 | 1.1 | 5.7 | 1.0 | 5.8 | 1.1 | 0.2 |
Final DAS28 score (mean ± SD) | 3.56 | 1.54 | 3.39 | 1.52 | 3.6 | 1.3 | 3.4 | 1.5 | 0.8 |
Difference in DAS28 score (mean ± SD) | 1.6 | 0.7 | 1.6 | 0.7 | 1.7 | 0.6 | 1.6 | 0.7 | 0.4 |
Baseline HAQ score (mean ± SD) | 1.40 | 0.58 | 1.44 | 0.65 | 1.63 | 0.59 | 1.461 | 0.633 | 0.002 |
Final HAQ score (mean ± SD) | 0.83 | 0.71 | 0.93 | 0.76 | 1.08 | 0.74 | 0.930 | 0.752 | 0.005 |
Difference in HAQ score (mean ± SD) | 0.60 | 0.69 | 0.51 | 0.75 | 0.60 | 0.70 | 0.545 | 0.734 | 0.1 |
Follow up | |||||||||
Completed last visit (n, %) | 132 | 56 | 391 | 51 | 82 | 60 | 605 | 53 | 0.46 |
Loss of follow up (n, %) | 102 | 44 | 375 | 49 | 54 | 40 | 531 | 47 | 0.07 |
Reasons | |||||||||
Adverse event | 33 | 32 | 174 | 46 | 16 | 30 | 223 | 42 | 0.001 |
Inefficacy | 30 | 29 | 87 | 23 | 12 | 22 | 129 | 24 | 0.5 |
Patient decision | 7 | 7 | 15 | 4 | 3 | 5 | 25 | 5 | 0.6 |
Unknown | 32 | 32 | 99 | 27 | 23 | 43 | 154 | 29 | 0.4 |